The venture accelerator for the longevity century.
Building the science-backed companies that will make Switzerland the global leader in longevity.
One platform across Switzerland’s two great institutions.
We connect the scientific and engineering strength of ETH Zurich with the finance, entrepreneurship and institutional networks of St. Gallen. That bridge is where breakthrough research becomes an investable company.
Switzerland has the science. We build the companies.
Swiss research leads the world, yet too little of it reaches the market as a company. The Human Performance Club exists to close that gap: converting the country’s scientific advantage into ventures that extend healthy human life, and doing it fast enough to define the field before others do.
Six frontiers where Swiss science becomes investable scale.
We back capital efficient, evidence based ventures with a fast path to validation and a defensible European right to win.
AI and Clinical Intelligence
Software that removes friction from prevention, diagnosis and care.
Preventive Diagnostics
Early detection and biomarkers that move medicine upstream.
Healthspan and Longevity
Interventions that extend not only lifespan, but healthy years.
Metabolic Health
The cardiometabolic frontier, the largest preventable disease burden.
Health Data Infrastructure
The interoperable rails beneath modern preventive care.
Longevity Finance
Prevention linked products for insurers, pensions and private wealth.
Direct access to Switzerland’s next generation of health ventures.
We are assembling a founding circle of family offices, private banks, insurers and strategic partners ahead of the 2027 cohort. Early participants shape the thesis, see deal flow first, and help define the standard for longevity investing in Europe.
- →First look at proprietary deal flowScience vetted, investor ready ventures from the ETH and HSG ecosystem, ahead of the wider market.
- →A seat on the evaluator boardShape selection criteria and diligence alongside leading operators, clinicians and investors.
- →Longevity finance intelligenceProprietary research on prevention economics, longevity linked products and the Swiss market.
- →Structured co-investment pathwaysQualified investor routes to participate directly as ventures mature.3
How we select ventures
- Founder and market fit with genuine technical depth
- A credible, peer reviewable scientific base
- Capital efficiency and speed to validation
- A defensible Swiss or European right to win
What we screen out
- Wellness claims without evidence
- Long cycle therapeutics as a core bet
- Capital intensive models with no near term proof
- Hype without a scientific threshold